RECOVERY Trial: Dexamethasone for COVID-19

In March 2020, as intensive care units across England filled with patients on mechanical ventilators, the University of Oxford launched a platform trial designed to test multiple COVID-19 treatments simultaneously within the NHS. RECOVERY (Randomised Evaluation of COVID-19 Therapy) opened across 176 hospitals, using an adaptive design that allowed arms to be added or dropped without closing the trial. Peter Horby and Martin Landray co-led the effort. Among the first agents tested was low-dose dexamethasone, a corticosteroid available at every hospital on earth, chosen because the pathophysiology of severe COVID-19 increasingly resembled a dysregulated inflammatory response rather than uncontrolled viral replication.

On June 16, 2020, investigators announced that 6 mg of dexamethasone daily for up to 10 days cut 28-day all-cause mortality from 25.7% to 22.9% in the overall population. The benefit was sharply concentrated by respiratory status. Among patients requiring invasive mechanical ventilation, 28-day mortality was 29.3% with dexamethasone versus 41.4% with usual care, a reduction of about one third. Among those on supplemental oxygen alone, it was 23.3% versus 26.2%. Patients receiving no respiratory support showed no benefit and a non-significant trend toward harm, a finding that argued against prophylactic steroid use in mild disease and indicated that the drug was treating the inflammatory injury, not the virus itself.

The WHO issued a statement the same day welcoming the results and said its clinical guidance would be updated accordingly, months before the formal paper appeared in the New England Journal of Medicine the following February. That sequence, public health action preceding peer-reviewed publication, reflected the emergency conditions and the quality of the RECOVERY platform's design. Dexamethasone is a decades-old generic corticosteroid that costs very little and was already stocked in hospital pharmacies at every income level. No logistical barrier stood between the evidence and its implementation.

RECOVERY continued enrolling into other arms after the dexamethasone result. Tocilizumab, an IL-6 receptor antagonist, and baricitinib, a JAK inhibitor, were subsequently shown to reduce mortality further in patients already receiving dexamethasone. Together, the three drugs gave clinicians a layered anti-inflammatory strategy for severe COVID-19. The RECOVERY platform's design became a template cited in subsequent infectious disease preparedness discussions, valued for the speed at which it generated credible answers without sacrificing randomized controls.